Scarica l'app Stockscreener
7.38
4.98%
0.35
Passage Bio Inc Borsa (PASG) Ultime notizie
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
Passage Bio's 2025 net loss narrows - TradingView
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Passage Bio Highlights PBFT02 FTD-GRN Biomarker Gains, Targets 2026 Readouts, Runway to Q1 2027 - Defense World
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio management to present at two healthcare conferences - MSN
Passage Bio Management to Present at Two Healthcare Conferences - MyChesCo
Recap Report: Can Passage Bio Inc ride the EV waveQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Moving Averages: What is the earnings history of Passage Bio Inc2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Nasdaq Moves: Can Passage Bio Inc. reach all time highs this yearBear Alert & Expert Approved Trade Ideas - mfd.ru
Can Passage Bio Inc. stock hit record highs againInsider Buying & Advanced Technical Analysis Signals - mfd.ru
Passage Bio to Participate in Upcoming Investor Conferences - Caledonian Record
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
What downside risks could hit Goldman Sachs Equal Weight U.S. stockJuly 2025 Catalysts & Accurate Entry/Exit Alerts - mfd.ru
Can Passage Bio Inc. outperform in the next rallyJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growth2025 Earnings Impact & Weekly Chart Analysis and Guides - mfd.ru
Is Passage Bio Inc.’s ROIC above industry averageJuly 2025 Rallies & Entry Point Strategy Guides - mfd.ru
Why Putnam ETF Trust Putnam BioRevolution stock appeals to dividend investorsMarket Volume Summary & Low Risk Growth Stock Ideas - mfd.ru
Buyout Rumor: Should I invest in Passage Bio Inc before earningsInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Coverage Initiated by Analysts at Chardan Capital - Defense World
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 - Defense World
Retail Surge: What is the dividend yield of Passage Bio Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Ideas: Can Passage Bio Inc. reach all time highs this yearQuarterly Portfolio Summary & Long-Term Growth Plans - mfd.ru
Gm1 Gangliosidosis Treatment Market Witness Booming Growth: - openPR.com
Earnings Miss: Is PAYC stock a buy or sellTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Gap Down: How does Passage Bio Inc perform in inflationary periodsWeekly Stock Summary & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Analyst Calls: Is Information Services Group Inc likely to announce a buyback2025 Risk Factors & High Conviction Buy Zone Picks - baoquankhu1.vn
Market Rankings: Why is Royce Small Cap Trust Inc stock going downProduct Launch & Low Drawdown Investment Ideas - baoquankhu1.vn
Insider Trends: Is TETRA Technologies Inc. a cyclical or defensive stockMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):